Artelo Biosciences
ARTL
8 hedge funds and large institutions have $152K invested in Artelo Biosciences in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
33% more funds holding
Funds holding: 6 → 8 (+2)
0.55% more ownership
Funds ownership: 1.01% → 1.56% (+0.55%)
31% less capital invested
Capital invested by funds: $220K → $152K (-$68.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$175K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$143K |
| 3 |
Morgan Stanley
New York
|
+$11.2K |
| 4 |
Citigroup
New York
|
+$4.78K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$213K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.93K |
| 3 |
DB
Danske Bank
Copenhagen K,
Denmark
|
-$13 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DS
1
DRW Securities
Chicago,
Illinois
| $78.9K | +$175K | +5,728 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $64.4K | +$143K | +4,676 | New |
|
|
3
Morgan Stanley
New York
| $5.05K | +$11.2K | +366 | +36,600% |
|
|
4
Citigroup
New York
| $2.19K | +$4.78K | +156 | +5,200% |
|
|
5
UBS Group
Zurich,
Switzerland
| $959 | +$1.23K | +40 | +133% |
|
6
Fidelity Investments
Boston,
Massachusetts
| $138 | +$306 | +10 | New |
|
7
Bank of America
Charlotte,
North Carolina
| $50 | +$61 | +2 | +100% |
|
|
RIL
8
Rothschild Investment LLC
Chicago,
Illinois
| $9 | +$31 | +1 | New |
|
|
9
Geode Capital Management
Boston,
Massachusetts
| – | -$213K | -5,344 | Closed |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$5.93K | -149 | Closed |
|
|
DB
11
Danske Bank
Copenhagen K,
Denmark
| – | -$13 | – | – |
|
ARTL Hedge Fund Activity: Q3 2025 in Review
8 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2025, worth a combined $152K — down 31% from $220K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ARTL positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $175K. The largest seller was Geode Capital Management, exiting entirely with an estimated $213K sold.
- 8 institutional investors held Artelo Biosciences (ARTL) as of Q3 2025, up from 6 in Q2 2025.
- Funds reported $152K of Artelo Biosciences stock for Q3 2025, down 31% quarter-over-quarter.
- 4 funds opened new Artelo Biosciences positions in Q3 2025 and 2 closed out, a net change of +2 holders.
- The largest Artelo Biosciences buyer in Q3 2025 was DRW Securities, an estimated $175K added.
- The largest Artelo Biosciences seller in Q3 2025 was Geode Capital Management, an estimated $213K sold.
Based on aggregated 13F filings for Q3 2025.